These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 16441427

  • 1. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib.
    Matsuo M, Sakurai H, Ueno Y, Ohtani O, Saiki I.
    Cancer Sci; 2006 Feb; 97(2):155-62. PubMed ID: 16441427
    [Abstract] [Full Text] [Related]

  • 2. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, Kuwano M.
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [Abstract] [Full Text] [Related]

  • 3. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.
    Breast Cancer Res; 2007 Apr; 9(4):R50. PubMed ID: 17686159
    [Abstract] [Full Text] [Related]

  • 4. Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib.
    Ueno Y, Sakurai H, Matsuo M, Choo MK, Koizumi K, Saiki I.
    Br J Cancer; 2005 May 09; 92(9):1690-5. PubMed ID: 15841081
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells.
    Tveteraas IH, Müller KM, Aasrum M, Ødegård J, Dajani O, Guren T, Sandnes D, Christoffersen T.
    J Exp Clin Cancer Res; 2012 Sep 11; 31(1):72. PubMed ID: 22967907
    [Abstract] [Full Text] [Related]

  • 6. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
    Shien T, Doihara H, Hara H, Takahashi H, Yoshitomi S, Taira N, Ishibe Y, Teramoto J, Aoe M, Shimizu N.
    Breast Cancer; 2004 Sep 11; 11(4):367-73. PubMed ID: 15604992
    [Abstract] [Full Text] [Related]

  • 7. Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes.
    Liu L, Zhao X, Pierre SV, Askari A.
    Am J Physiol Cell Physiol; 2007 Nov 11; 293(5):C1489-97. PubMed ID: 17728397
    [Abstract] [Full Text] [Related]

  • 8. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C.
    Adv Med Sci; 2011 Nov 11; 56(2):275-84. PubMed ID: 22037177
    [Abstract] [Full Text] [Related]

  • 9. Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?
    Park YK, Kim KM, Lee YJ, Kim KH, Lee SG, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ.
    J Korean Med Sci; 2011 Feb 11; 26(2):214-21. PubMed ID: 21286012
    [Abstract] [Full Text] [Related]

  • 10. Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes.
    Dajani OF, Meisdalen K, Guren TK, Aasrum M, Tveteraas IH, Lilleby P, Thoresen GH, Sandnes D, Christoffersen T.
    J Cell Physiol; 2008 Feb 11; 214(2):371-80. PubMed ID: 17654493
    [Abstract] [Full Text] [Related]

  • 11. Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells.
    Müller KM, Tveteraas IH, Aasrum M, Ødegård J, Dawood M, Dajani O, Christoffersen T, Sandnes DL.
    BMC Cancer; 2011 Oct 02; 11():421. PubMed ID: 21961726
    [Abstract] [Full Text] [Related]

  • 12. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
    Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, Kumar R.
    Mol Cancer Ther; 2003 Apr 02; 2(4):345-51. PubMed ID: 12700278
    [Abstract] [Full Text] [Related]

  • 13. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R, Gemma A, Kosaihira S, Kokubo Y, Chen M, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Kudoh S.
    BMC Cancer; 2006 Dec 06; 6():277. PubMed ID: 17150102
    [Abstract] [Full Text] [Related]

  • 14. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S.
    J Cell Physiol; 2006 May 06; 207(2):420-7. PubMed ID: 16419029
    [Abstract] [Full Text] [Related]

  • 15. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A.
    Int J Cancer; 2014 Jun 01; 134(11):2560-71. PubMed ID: 24374738
    [Abstract] [Full Text] [Related]

  • 16. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
    Failly M, Korur S, Egler V, Boulay JL, Lino MM, Imber R, Merlo A.
    Mol Cancer Ther; 2007 Feb 01; 6(2):773-81. PubMed ID: 17308073
    [Abstract] [Full Text] [Related]

  • 17. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
    Liu X, Carlisle DL, Swick MC, Gaither-Davis A, Grandis JR, Siegfried JM.
    Exp Cell Res; 2007 Apr 15; 313(7):1361-72. PubMed ID: 17349623
    [Abstract] [Full Text] [Related]

  • 18. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S.
    Ann Oncol; 2002 Jan 15; 13(1):65-72. PubMed ID: 11863114
    [Abstract] [Full Text] [Related]

  • 19. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S.
    Cancer Chemother Pharmacol; 2006 Nov 15; 58(5):577-84. PubMed ID: 16532343
    [Abstract] [Full Text] [Related]

  • 20. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M.
    Endocr Relat Cancer; 2005 Dec 15; 12(4):983-98. PubMed ID: 16322337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.